Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRIEF
April 19, 2004
- Kyowa Hakko Distributes Poster to Prevent Errors in Dispensing Allelock
April 19, 2004
- ACCJ's Recommendation on Medical Devices Published
April 19, 2004
- 8.5% of Patients Using Generic Statins: EPOCA Survey
April 19, 2004
- MEDICAL DEVICE NEWS IN BRIEF
April 19, 2004
- Dainippon Introduces Performance-based Personnel System
April 19, 2004
- Combined Sales of JCROA Member Companies to Exceed \50 Bil. in 2004: Mr Nakamura
April 19, 2004
- BUSINESS NEWS IN BRIEF
April 19, 2004
- BULLETIN
April 19, 2004
- Website News
April 19, 2004
- PMDA to Expedite NDA Review Process, Strengthen Safety Measures
April 19, 2004
- REGULATORY NEWS IN BRIEF
April 19, 2004
- Companies Welcome Newcomers
April 12, 2004
- OTC NEWS IN BRRIEF
April 12, 2004
- Informed Choice Better than Informed Consent: JPMA Consumer Survey
April 12, 2004
- Japanese Healthcare Q&A (7)
April 12, 2004
- BUSINESS NEWS IN BRIEF -1-
April 12, 2004
- DIAGNOSTIC NEWS IN BRIEF
April 12, 2004
- BUSINESS NEWS IN BRIEF -2-
April 12, 2004
- WORLD NEWS IN BREIF
April 12, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…